A Phase I Study to Evaluate the Effect of Different Liquid Vehicles on the Pharmacokinetics of MK-3214 in Healthy Volunteers with Hypercholesterolaemia

The primary objective of this study is to evaluate the pharmacokinetics of MK-3214 when administered with various liquids in healthy participants. This investigation is relevant for determining the influence of different beverage types on the absorption and systemic exposure of the study drug.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers who are male. Participants fall within the specific age range denoted by code 3. No information was provided regarding hypercholesterolaemia, lifestyle factors, or specific selection processes.

This Phase 3 clinical trial is designed to evaluate the effects of MK-3214 when administered with various liquids in healthy participants. The research methodology involves a structured sequence of study visits beginning with a screening visit to assess eligibility. Following the initial assessment, participants will undergo the study procedures, which include subsequent follow-up visits to monitor responses. The protocol concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific visit schedule. Early termination from the study may occur based on predefined clinical criteria or safety protocols. The estimated recruitment period for this study is from March 2026 to May 2026.

The assessment of efficacy in this study regarding hypercholesterolaemia is not specified.